Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828899 | 0.87 | MAPK1 (0.60) | LMNAPTGS2ALDH1A1MAPTMEN1 | |
| SCHEMBL9628550 | 0.82 | APEX1 (0.46) | LMNAPTGS2ALDH1A1MAPTKMT2A | |
| SCHEMBL5733156 | 0.82 | LMNA (0.56) | LMNAPTGS2ALDH1A1MAPTPTGS1 | |
| SCHEMBL12638410 | 0.82 | PTGS2 (0.58) | LMNAPTGS2ALDH1A1MAPTMEN1 | |
| SCHEMBL863161 | 0.82 | PTGS2 (0.58) | LMNAPTGS2ALDH1A1MAPTPTGS1 | |
| SCHEMBL10950526 | 0.81 | EPAS1 (0.52) | LMNAPTGS2APEX1SLC6A4PTGS1 | |
| SCHEMBL3752334 | 0.80 | LMNA (0.50) | LMNAPTGS2ALDH1A1MAPT | |
| SCHEMBL1370002 | 0.80 | LMNA (0.55) | LMNAPTGS2ALDH1A1MAPTMEN1 | |
| SCHEMBL12469250 | 0.80 | PTGS2 (0.57) | LMNAPTGS2ALDH1A1MAPTPTGS1 | |
| SCHEMBL687066 | 0.80 | LMNA (0.55) | LMNAPTGS2ALDH1A1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718605-B1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH CORP (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| CN-122070618-A | Graphite-based electrochemical cell | 铌博尔特有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099505-A1 | SYSTEM FOR CONTROLLING BATTERY TEMPERATURE | NYOBOLT LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-4634118-B1 | NIOBIUM METAL OXIDE | NYOBOLT LTD (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250337004-A1 | COMPOSITE POLYMER CERAMIC ELECTROLYTE | HSBC VENTURES USA INC. | 2025-10-30 | — | — | US | disclosed |
| EP-4634118-A1 | NIOBIUM METAL OXIDE | Nyobolt Limited (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-4623496-A1 | CHARGING AND DISCHARGING SYSTEM | Nyobolt Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-12407020-B2 | High ionic conductivity polymer electrolyte compositions for alkali and beyond alkali metal batteries | UT-BATTELLE, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025104256-A1 | POWER CONTROLLER | NYOBOLT LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-4220652-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-02 | — | — | US | disclosed |
| US-4203909-A | ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4200578-A | ANTIULCER AGENTS, BLOCKING AGENTS, ANTISECRETORY AGENTS | BRISTOL-MYERS COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4200760-A | ANTIULCER, H2-RECEPTOR BLOCKING AGENTS | BRISTOL-MYERS COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4153704-A | HETEROCYCLIC-ALKYL-AMINO SUBSTITUTED, ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
| US-4124717-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-11-07 | — | — | US | disclosed |
| US-4080459-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
| US-4013769-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | LMNA 3970/4885PTGS2 2406/4885ALDH1A1 343/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | LMNA 3970/4885PTGS2 2406/4885ALDH1A1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.